ELDN — Eledon Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404281 ·
Last close
$3.85
Market Cap
$297.17M
52W High
$4.49
52W Low
$3.10
ADV30
1,618,092
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,181,000 | -39,025,000 | 146,667,000 | 6,152,000 | 101,903,000 |
| Dec 2025 | 0 | — | -21,484,000 | -10,447,000 | 169,009,000 | 22,808,000 | 87,924,000 |
| Sep 2025 | 0 | — | -19,070,000 | -17,459,000 | 129,857,000 | 3,669,000 | 94,497,000 |
| Jun 2025 | 0 | — | -24,733,000 | -11,216,000 | 144,909,000 | 5,741,000 | 94,575,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,893,000
Investing CF
$12,857,000
Financing CF
$53,692,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-440,228,000
Inventory
—
Receivables
$583,000
ST Investments
$104,937,000
EBIT TTM
$-86,468,000
Pretax Income TTM
$-78,112,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,251,000 | -45,617,000 | 169,009,000 | 87,924,000 | — | -62,341,000 |
| Dec 2024 | 0 | -70,577,000 | -36,184,000 | 177,405,000 | 114,959,000 | — | -47,271,000 |
| Dec 2023 | 0 | -43,000,000 | -116,537,000 | 89,066,000 | 81,858,000 | — | -39,527,000 |
| Dec 2022 | 0 | -39,780,000 | -87,966,000 | 92,793,000 | 8,610,000 | — | -28,424,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.72
Max Pain — expiry 2026-08-21
max pain strike: $5.00 · spot: $3.85 · call oi: 3,889 · put oi: 14,978
Expected Move to 2026-08-21:
±$1.38
(35.71%) —
implied range
$2.47 –
$5.22
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $294.16M | $0.18 | — |
| IFRX | InflaRx N.V. | $301.95M | $2.05 | — |
| GLSI | Greenwich LifeSciences, Inc. | $290.63M | $19.80 | — |
| ORGO | Organogenesis Holdings Inc. | $308.82M | $2.40 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $285.95M | $2.12 | — |
News headlines (Yahoo Finance, 1h cache)
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
2026-07-08 13:15 · Yahoo
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
2026-07-01 13:30 · Yahoo
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
2026-06-25 11:00 · Yahoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
2026-06-22 11:00 · Yahoo
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
2026-06-16 13:40 · Yahoo
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart
2026-06-10 18:22 · Yahoo
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
2026-06-08 11:00 · Yahoo
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific
2026-06-04 20:31 · Yahoo
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
2026-05-29 13:40 · Yahoo
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
2026-05-27 11:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.